Forecasting Cytokine Storms with New Predictive Biomarkers.
T cells genetically modified with CD19 chimeric antigen receptors have produced impressive clinical responses in patients with refractory B-cell malignancies, but therapeutic responses are often accompanied by cytokine release syndrome (CRS), which can cause significant morbidity and mortality. Teachey and colleagues have identified predictive biomarkers for this complication that may allow testing of earlier intervention with agents such as the IL6 receptor blocker tocilizumab to evaluate whether CRS can be ameliorated without jeopardizing clinical responses. Cancer Discov; 6(6); 579-80. ©2016 AACR.See related article by Teachey et al., p. 664.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas. Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas.
Rayne H
RH
Rouce
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas. hheslop@bcm.edu.
Helen E
HE
Heslop
D018941:Antigens, CD19 / Q000276:immunology*; D015415:Biomarkers; D016207:Cytokines; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
D018941:Antigens, CD19; D015415:Biomarkers; D016207:Cytokines; D011948:Receptors, Antigen, T-Cell